526-36-3

Basic information

• Product Name: 2-(4-TERT-BUTYL-2,6-DIMETHYL-BENZYL)-4,5-DIHYDRO-1H-IMIDAZOLE
• Synonyms: XYLOMETAZOLINE;2-(4-TERT-BUTYL-2,6-DIMETHYL-BENZYL)-4,5-DIHYDRO-1H-IMIDAZOLE;AKOS BBS-00000259;1h-imidazole,2-((4-(1,1-dimethylethyl)-2,6-dimethylphenyl)methyl)-4,5-dihydr;2-(4-tert-butyl-2,6-dimethylbenzyl)-2-imidazolin;2-(4-tert-Butyl-2,6-dimethylbenzyl)-2-imidazoline;2-[[4-(1,1-Dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-1H-imidazole;2-Imidazoline, 2-(4-tert-butyl-2,6-dimethylbenzyl)-
• CAS NO: 526-36-3
• Molecular Formula: C₁₆H₂₄N₂
• Molecular Weight: 244.38
• EINECS: 208-390-6
• Mol File: 526-36-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 131-133°
• Boiling Point: 394.2 °C at 760 mmHg
• Flash Point: 192.2 °C
• Appearance: /
• Density: 1 g/cm³
• Vapor Pressure: 4.56E-06mmHg at 25°C
• PKA: pKa 10.6±0.1(H2O t = 22.0) (Uncertain)
• CAS DataBase Reference: 2-(4-TERT-BUTYL-2,6-DIMETHYL-BENZYL)-4,5-DIHYDRO-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-TERT-BUTYL-2,6-DIMETHYL-BENZYL)-4,5-DIHYDRO-1H-IMIDAZOLE(526-36-3)
• EPA Substance Registry System: 2-(4-TERT-BUTYL-2,6-DIMETHYL-BENZYL)-4,5-DIHYDRO-1H-IMIDAZOLE(526-36-3)

Safety Data

• Hazardous Substances Data: 526-36-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 526-36-3 differently. You can refer to the following data:
1. Adrenergic (vasoconstrictor).
2. Xylometazoline is used for rhinitis, laryngitis, sinusitis, inflammation of antrum of Highmore, and allergic illnesses of the nasal cavity and throat.

Synthesis

Xylometazoline, 2-(4-tert-butyl-2,6-dimethylbenzyl)-2-imidazoline (11.1.40), is also synthesized in a single reaction by cyclocondensation of 4-tert-butyl-2,6- dimethylbenzylcyanide with ethylendiamine [43,44].

InChI:InChI=1/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)/p+1

Upstream product

• 84803-57-6 4-tert-butyl-2,6-dimethylphenylacetonitrile 
• 107-15-3 ethylenediamine 

Relevant articles and documents

Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives

The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R1, R2, A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

Feed additive for improving growth in agricultural animals

By using α-mimetics, particularly compounds of general formulae I to III and the compounds listed in Table I, as feed additives in fattening animals, it has surprisingly been possible to improve the daily weight gain, the utilisation of fodder and the ratio of muscle to fat in favor of the proportion of muscle and protein.